SCHEMBL5437118

SCHEMBL5437118

O=c1oc(-c2cccc3ccccc23)nc2ccncc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F7 P08709 2/20 0.56
F3 P13726 2/20 0.56
F10 P00742 1/20 0.56
F2 P00734 3/20 0.53
C1R P00736 8/20 0.52
KMT2A Q03164 4/20 0.52
PLG P00747 1/20 0.52
KLK1 P06870 1/20 0.52
PRSS1 P07477 1/20 0.52
C1S P09871 1/20 0.52
ATM Q13315 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
MEN1 O00255 3/20 0.48
MAPT P10636 2/20 0.48
ELANE P08246 2/20 0.48
TNF P01375 1/20 0.48
KLK3 P07288 1/20 0.46
ESR1 P03372 1/20 0.46
ESR2 Q92731 1/20 0.46
ALDH1A1 P00352 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5433314 0.89 F7 (0.71) F7F3F10F2C1R
SCHEMBL2816912 0.85 C1R (0.69) F2C1RKMT2APLGKLK1
SCHEMBL5437151 0.84 F2 (0.51) F7F3F10F2C1R
SCHEMBL9475739 0.80 C1R (0.76) F2C1RKMT2APLGKLK1
SCHEMBL26833301 0.78 ALDH1A1 (0.59) F7F3F10KMT2AATM
SCHEMBL5257308 0.77 C1R (0.72) F2C1RKMT2APLGKLK1
SCHEMBL4194659 0.77 C1R (0.72) F2C1RKMT2APLGKLK1
SCHEMBL5261384 0.77 C1R (0.58) F2C1RKMT2APLGKLK1
SCHEMBL2537274 0.75 ELANE (0.73) F2C1RKMT2APLGKLK1
SCHEMBL9475884 0.75 C1R (0.78) F2C1RKMT2APLGKLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070225292-A1 Therapeutic Compounds: Pyridine as Scaffold ASTRAZENECA AB (SE) 2007-09-27 US disclosed
US-20070225292-A1 Therapeutic Compounds: Pyridine as Scaffold ASTRAZENECA AB (SE) 2007-09-27 US disclosed
US-20070225292-A1 Therapeutic Compounds: Pyridine as Scaffold ASTRAZENECA AB (SE) 2007-09-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225292-A1 Therapeutic Compounds: Pyridine as Scaffold OPRL1, OPRK1, P2RX3 F7 2801/4885F3 90/4885F10 1660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.